Lack of vascular endothelial growth factor receptor-2/Flk1 signaling does not affect substantia nigra development
Abstract
Oxygen tension is critical for proliferation of human and murine midbrain-derived neural precursor cells (mNPCs). Lack of hypoxia-inducible factor-1α (HIF1α) impairs midbrain dopaminergic neurogenesis which could be rescued by vascular endothelial growth factor (VEGF) via VEGFR-2 signaling. Here, we conditionally inactivated the VEGFR-2, encoded by the fetal liver kinase 1 (Flk1) gene, in murine NPCs to determine its role in proliferation and survival in vitro as well as survival of dopaminergic neurons in vivo. Flk1 conditional knock-out (Flk1 CKO) mice showed no general brain phenotype. There was no midbrain-specific impairment of NPC proliferation as seen in HIF1α CKO mice. In the substantia nigra (SN) of adult Flk1 CKO mice, nonbiased stereological cell counts revealed no reduction of TH-positive neurons of Flk1 CKO mice compared with control Cre/wt mice (in which the wild-type Flk1 allele is expressed in parallel with the Cre recombinase allele). In conclusion, VEGF receptor signaling seems not to be relevant to the development and survival of substantia nigra dopaminergic neurons within the hypoxia-HIF1α signaling pathway.
Additional Information
© 2013 Elsevier Ireland Ltd. Received 13 June 2013. Received in revised form 29 July 2013. Accepted 11 August 2013. We acknowledge Sylvia Kanzler, Silvia Krakau, Cornelia Mai,Rosi Mueller, Antje Muschter for excellent technical assistance and Grit Weselek for fruitful discussions. The work was supported in part by the Deutsche Parkinson-Gesellschaft (DPG) to A.H., by a GlaxoSmithKline fellowship to A.H., by the Deutsche Forschungsgemeinschaft (DFG) through the DFG-Research Center for Regenerative Therapies Dresden (CRTD) to A.H. and A.S. and though the SFB 655 to A.S. and G.B. The authors report no conflict of interest.Additional details
- Eprint ID
- 42629
- DOI
- 10.1016/j.neulet.2013.08.031
- Resolver ID
- CaltechAUTHORS:20131121-142429534
- Deutsche Parkinson-Gesellschaft (DPG)
- GlaxoSmithKline fellowship
- DFG-Research Center for Regenerative Therapies Dresden (CRTD)
- SFB
- 655
- Created
-
2013-11-21Created from EPrint's datestamp field
- Updated
-
2021-11-10Created from EPrint's last_modified field